{"id":"NCT00097500","sponsor":"AstraZeneca","briefTitle":"Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes","officialTitle":"A Phase 3, Randomized, Open Label, Comparator-Controlled, Parallel Group, Multicenter Study to Compare the Effects of Exenatide and Insulin Glargine on Beta Cell Function and Cardiovascular Risk Markers in Subjects With Type 2 Diabetes Treated With Metformin Who Have Not Achieved Target HbA1c","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-09","primaryCompletion":"2009-12","completion":"2009-12","firstPosted":"2004-11-25","resultsPosted":"2011-01-10","lastUpdate":"2015-04-07"},"enrollment":69,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"exenatide","otherNames":["Byetta"]},{"type":"DRUG","name":"Insulin glargine","otherNames":["Lantus"]},{"type":"DRUG","name":"Metformin","otherNames":[]}],"arms":[{"label":"Exenatide Arm","type":"EXPERIMENTAL"},{"label":"Insulin Glargine Arm","type":"ACTIVE_COMPARATOR"}],"summary":"This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (LantusÂ® injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.","primaryOutcome":{"measure":"Beta-cell Function After 52 Weeks of Therapy","timeFrame":"Baseline (week -2) and 52 weeks","effectByArm":[{"arm":"Exenatide Arm","deltaMin":2.89,"sd":0.27},{"arm":"Insulin Glargine Arm","deltaMin":1.15,"sd":0.11}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":3,"countries":["Finland","Netherlands","Sweden"]},"refs":{"pmids":["19196887","39963952","31078666","21868779","20494360"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":36},"commonTop":["Nausea","Hypoglycemia","Influenza","Dyspepsia","Arthralgia"]}}